Research programme: anti-infectives - Novartis/Merck
Alternative Names: Anti-infectives research programme - NovartisLatest Information Update: 24 Oct 2021
At a glance
- Originator Cubist Pharmaceuticals; Novartis
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 23 Feb 2009 Discontinued - Preclinical for Bacterial infections in USA (unspecified route)
- 02 Jul 2002 This programme is still in active development
- 04 Aug 1999 Preclinical development for Bacterial infections in USA (Unknown route)